Total buying$00 buys
RXRX
RECURSION PHARMACEUTICALS, INC.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$367k2 sells
Net open-market−$367kBuying minus selling
Active insiders4Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 07, 2026
Open-market transaction mix · 2 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 2 | 2 | $0 | $367k | -$367k |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (4)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- BB-$242.0k
- HR-$125.0k
- DZ+$0
- LY+$0
RXRX transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
RXRXRECURSION PHARMACEUTICALS, INC. | Borgeson BlakeDIR | S · sale10b5-1 detectedSEC filing ↗ | -$242kView disclosure → | |
RXRXRECURSION PHARMACEUTICALS, INC. | Hershberg RobertDIR | M · exercise10b5-1 detectedDerivative securitySEC filing ↗ | -$55.5kView disclosure → | |
RXRXRECURSION PHARMACEUTICALS, INC. | Hershberg RobertDIR | S · sale10b5-1 detectedSEC filing ↗ | -$125kView disclosure → | |
RXRXRECURSION PHARMACEUTICALS, INC. | Hershberg RobertDIR | M · exercise10b5-1 detectedSEC filing ↗ | $55.5kView disclosure → | |
RXRXRECURSION PHARMACEUTICALS, INC. | Dar ZavainDIR | A · grantSEC filing ↗ | $0View disclosure → | |
RXRXRECURSION PHARMACEUTICALS, INC. | Li Dean YDIR | A · grantSEC filing ↗ | $0View disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period6transactionstxns
- A · Grants / awards · dominant2 · 33%
- M · Option exercise2 · 33%
- S · Open-market sells2 · 33%
Activity by reported role
A joint filing can contribute to multiple rolesDirector6
Reported Holdings After
Separated by insider, security, and ownership type
Hershberg RobertClass A Common Stock · Direct
162,156Oct 06, 2026
Li Dean YClass A Common Stock · Direct
1,476,707Oct 01, 2026
Dar ZavainClass A Common Stock · Direct
245,371Oct 01, 2026
Hershberg RobertStock Option (Right to Buy) · Direct
500,000Oct 06, 2026
Borgeson BlakeClass A Common Stock · Direct
6,108,287Oct 06, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
RECURSION PHARMACEUTICALS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at RECURSION PHARMACEUTICALS, INC.?
Borgeson Blake, HERSHBERG ROBERT, Dar Zavain, Li Dean Y.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Borgeson Blake reported a sale on Oct 06, 2026 valued at $242k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $367,000.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.